Vivus posts more positive ED data

Vivus is reporting additional results from trial of its ED drug avanafil. Patients who attempted intercourse within 15 minutes of dosing were successful 67 percent, 69 percent and 72 percent of the time on 50, 100 and 200 mg of the drug, respectively. Only 29 percent of patients on placebo were successful. The company announced in November that the drug had hit all its primary endpoints in a Phase III trial.

In the release, Vivus claims patients and physicians both feel rapid onset of ED therapies is a key to the drug's success. "A recent study in 1,900 patients with ED showed that 75 percent of patients identified rapid effect as an important treatment expectation," states Charles Bowden, M.D., Senior Director, Clinical Development at Vivus. If approved, avanafil rapid onset should help it carve out a place in the already crowded ED market.

Vivus has gotten off to a strong start in 2010. In addition to the results announced today, the company revealed earlier this month that its highly anticipated experimental obesity drug Qnexa significantly reduced sleep apnea in a mid-stage trial.

- see Vivus' release

Suggested Articles

Inovio CEO J. Joseph Kim is undeterred by short sellers and other detractors who doubt his company can shuttle a COVID-19 DNA vaccine to market.

Adding entinostat to hormone therapy did not help patients with HR-positive, HER2-negative breast cancer live longer.

The data add to the evidence in support of the IL-6 drug ahead of a FDA decision to approve it in a rare disease served by Alexion’s Soliris.